Home Covid News and Updates Covaxin booster dose increases immune response by 40 times, gives long-term immunity against COVID-19: Bharat Biotech

Covaxin booster dose increases immune response by 40 times, gives long-term immunity against COVID-19: Bharat Biotech

by Vaishali Sharma

The administration of the third dose of Bharat Biotech’s COVID-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination dramatically increased neutralising antibody responses against both homologous and heterologous strains (Alpha, Beta, Delta, Delta Plus, and Omicron) and showed increased memory B cell response in subjects in controlled clinical trials, the company announced on Wednesday.

According to the company, the findings are based on a comprehensive study that demonstrated multiple benefits of Covaxin, including long-term immune response, cell mediated immunity, booster dose safety, immunogenicity against spike protein, N protein, and neutralising antibody responses against alpha, beta, delta, delta plus, and omicron variants.

According to the study, Covaxin-induced strong T cell responses remained for six months following antibody decrease. These T cell responses in vaccinated people were tracked for up to 12 months, regardless of whether the third dosage was received. T cell responses, in turn, aid in the production of B cell memory responses in response to antigen re-exposure. As a result, Covaxin gives long-term immunity.

Also Read: J&K revamps Covid protocols in public places amid resurge

According to Bharat Biotech, immune responses decreased after six months but surged by 40 times in those who got a booster dosage. When tested against variations of concern, immune responses lasted up to 12 months.

The trial included 184 participants who were randomly assigned to either a booster dose of BBV152 or a placebo 6 months following the initial series of two doses.

According to the business, subjects were examined for safety, neutralising antibody responses against worry variants, binding antibodies against spike protein, RBD, N proteins, and memory T and B cell responses to indicate cell-mediated immunity.

Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Our team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD and N proteins. Post booster dose, it has proven to neutralize antibody responses against variants of concern and long term protection through memory T and B cell responses. We have now achieved our goal of developing a safe and efficacious vaccine with long-term protection against a spectrum of variants.”

Covaxin, according to Bharat Biotech, is manufactured in such a way that the same dosage may be given to adults and children for both main and booster doses, making it a universal vaccine.

Bharat Biotech claims to have more than 50 million doses of Covaxin on hand, ready to be delivered as needed.

Follow Medically Speaking on Twitter Instagram Facebook

You may also like